CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-19-0946
Abstract: Platinum-based chemoradiotherapy is a mainstay of organ-preserving therapy for patients with head and neck squamous cell carcinoma cancer (HNSCC). However, the disease eventually becomes resistant to treatment necessitating new therapies. Checkpoint kinase 1 and 2… read more here.
Keywords: cisplatin radiation; notch signaling; prexasertib; cell ... See more keywords
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
Sign Up to like & getrecommendations! Published in 2020 at "Oncotarget"
DOI: 10.18632/oncotarget.27443
Abstract: Background: Addition of nimotuzumab to weekly cisplatin and radiation improves outcomes in head and neck cancer. HPV negative oropharyngeal cancer has unsatisfactory treatment outcomes and is a candidate for escalation of treatment. We wanted to… read more here.
Keywords: cisplatin radiation; arm; hpv negative; cisplatin ... See more keywords
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14133160
Abstract: Simple Summary Head and neck cancers (HNSCCs), especially in the advanced stages, are predominantly treated by radiochemotherapy, including cisplatin. The cure rates are clearly higher for HPV-positive HNSCCs when compared to HPV-negative HNSCCs. For both… read more here.
Keywords: hpv negative; cisplatin radiation; bez235; hpv positive ... See more keywords